| Category | HSPB9 summary | Evidence |
|---|---|---|
| Approved gene/protein identity | **HSPB9** encodes **heat shock protein beta-9** in **Homo sapiens**; alternative names include **CT51** and **cancer/testis antigen 51**. It is a member of the mammalian **small heat shock protein (HSPB/HSP20)** family. | (pqac-00000007, pqac-00000010) |
| Protein family / class | Classified as a **small heat shock protein (sHSP)**, i.e., a low-molecular-weight, ATP-independent chaperone family characterized by a conserved **α-crystallin domain** with variable N- and C-terminal regions. Compared with other HSPBs, HSPB9 is among the least functionally characterized members. | (pqac-00000001, pqac-00000011) |
| Molecular weight | Reported molecular mass is **17.5 kDa**. | (pqac-00000007, pqac-00000010) |
| Gene location | Chromosomal location reported as **17q21.2**. | (pqac-00000010) |
| Domain architecture | UniProt/domain-based annotation and family placement indicate a conserved **α-crystallin / Hsp20 domain** typical of sHSPs; by family analogy this implies a central conserved domain flanked by more variable termini. | (pqac-00000001, pqac-00000011) |
| Alternative names / antigen status | HSPB9 is also called **CT51** and has been reported as a **cancer/testis antigen (CTA)** because it is normally testis-restricted yet detectable in certain tumors. | (pqac-00000007, pqac-00000010) |
| Tissue expression pattern | Expression is **testis-specific/restricted**, with expression **confined to testis germ cells**. Relative to other HSPBs, this is unusual because many HSPBs are ubiquitous or muscle/neuronal enriched, whereas **HSPB9 and HSPB10 are testis-specific**. | (pqac-00000007, pqac-00000010, pqac-00000011) |
| Developmental / cell-type expression | Expression **varies during spermatogenesis**, supporting a likely role in male germ-cell biology, though the precise function remains unproven. | (pqac-00000007) |
| Subcellular localization | Reported localization is **cytosol and nucleus**. A review also notes that HSPB9 **lacks a canonical nuclear localization signal**, so nuclear entry may depend on binding partners. | (pqac-00000010, pqac-00000013) |
| Known interaction partners | The best-described partner is **TCTEL1 / DynLT1 (DYNLT1)**, a **dynein light-chain subunit**. Interaction is reported to occur via the **C-terminus** of HSPB9. | (pqac-00000007, pqac-00000010) |
| Inferred functional implication of interaction | Because DynLT1/TCTEL1 is part of the **dynein transport machinery**, the HSPB9 interaction suggests a possible role in **intracellular transport-related processes** in germ cells and/or tumor cells; however this remains **hypothetical** rather than experimentally established. | (pqac-00000007, pqac-00000010, pqac-00000013) |
| Oligomerization / biophysical state | Unlike many other HSPBs, **studies on HSPB9 oligomerization are missing**. This is a major gap because oligomer dynamics usually regulate sHSP chaperone activity. | (pqac-00000007, pqac-00000011) |
| Chaperone activity | Although family membership implies potential **ATP-independent holdase/chaperone** behavior, **direct experimental evidence for HSPB9 chaperone activity, substrate spectrum, or anti-aggregation capacity is lacking**. | (pqac-00000007, pqac-00000011) |
| Enzymatic activity / substrate specificity | **No enzymatic activity is known**; HSPB9 is not described as an enzyme. **No specific client/substrate proteins** have been validated beyond the reported interaction with DynLT1/TCTEL1. | (pqac-00000007, pqac-00000010) |
| Stress inducibility | Current sources emphasize testis-restricted expression and do **not** provide clear evidence that HSPB9 is a classic heat-inducible stress protein in the way some other HSPBs are. | (pqac-00000007, pqac-00000010) |
| Disease / cancer relevance | HSPB9 has been **detected in tumors**, which underlies its CTA designation, but **its role in tumorigenesis has not been investigated in depth** and **no disease-causing mutations have been identified**. | (pqac-00000007, pqac-00000010) |
| Evolutionary note | Among orthologous HSPBs, HSPB9 has been described as having the **most divergent sequence between mouse and human**, suggesting rapid specialization or lineage-specific divergence. | (pqac-00000007) |
| Comparison with other HSPBs | In contrast to better-studied HSPBs such as **HSPB1, HSPB5, HSPB6, HSPB7, and HSPB8**, which have defined roles in cytoskeletal maintenance, apoptosis, autophagy, or muscle physiology, **HSPB9 lacks equivalent mechanistic characterization**. | (pqac-00000001, pqac-00000003, pqac-00000005, pqac-00000006, pqac-00000007) |
| Key current knowledge gaps | Major open questions include: **true molecular function**, **client proteins/substrates**, **oligomeric organization**, **whether it acts as a bona fide chaperone**, **its exact role in spermatogenesis**, **the significance of nuclear localization**, and **whether CTA expression in cancer has diagnostic or therapeutic relevance**. | (pqac-00000007, pqac-00000010, pqac-00000011) |


*Table: This table compiles the currently known features of human HSPB9/CT51, including molecular properties, expression, localization, interaction data, and major evidence gaps. It is useful because HSPB9 is poorly characterized, so the table distinguishes supported facts from family-based inference and unresolved questions.*